| Globant, Doximity, Applied Materials And Other Big Stocks Moving Lower In Friday's Pre-Market Session |
U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Friday. |
benzinga.com |
2025-05-16 13:09:59 |
Czytaj oryginał (ang.) |
| Doximity Stock Plunges Despite Q4 Earnings & Sales Beat, Margins Up |
DOCS reports robust growth in unique active users and sales of workflow tools, driving the top and bottom lines. First-quarter fiscal 2026 sales outlook below estimates. |
zacks.com |
2025-05-16 13:01:11 |
Czytaj oryginał (ang.) |
| DOXIMITY ALERT: Bragar Eagel & Squire, P.C. is Investigating Doximity, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm |
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Doximity, Inc. (NYSE: DOCS) on behalf of long-term stockholders following a class action complaint that was filed against Doximity on April 17, 2024 with a Class Period from February 9, 2022, to April 1, 2024. Our investigation concerns whether the board of directors of Doximity have breached their fiduciary duties to the company. |
globenewswire.com |
2025-05-16 01:00:00 |
Czytaj oryginał (ang.) |
| Doximity, Inc. (DOCS) Q4 2025 Earnings Call Transcript |
Doximity, Inc. (NYSE:DOCS ) Q4 2025 Earnings Conference Call May 15, 2025 5:00 PM ET Company Participants Perry Gold - Head of IR Jeff Tangney - Co-Founder and CEO Anna Bryson - CFO Nate Gross - Co-Founder and CSO Conference Call Participants Brian Peterson - Raymond James Michael Cherny - Leerink Partners Elizabeth Anderson - Evercore ISI Ryan MacDonald - Needham Jared Haase - William Blair Allen Lutz - Bank of America Scott Schoenhaus - KeyBanc Ann Samuel - JPMorgan Richard Close - Canaccord Genuity Jessica Tassan - Piper Sandler Steven Veliquette - Mizuho Securities Jeff Garro - Stephens David Roman - Goldman Sachs Jailendra Singh - Truist Craig Hettenbach - Morgan Stanley Operator Good day, everyone, and welcome to the Doximity Q4 2025 Earnings Call. At this time, I will hand the call over to Perry Gold, Head of IR. |
seekingalpha.com |
2025-05-16 00:35:24 |
Czytaj oryginał (ang.) |
| Doximity (DOCS) Surpasses Q4 Earnings and Revenue Estimates |
Doximity (DOCS) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.25 per share a year ago. |
zacks.com |
2025-05-15 22:16:11 |
Czytaj oryginał (ang.) |
| Doximity Stock Drops 20% After Outlook Disappoints |
Shares of Doximity plummeted late Thursday after the telehealth software company dished out a disappointing outlook. |
investopedia.com |
2025-05-15 21:55:40 |
Czytaj oryginał (ang.) |
| Doximity Announces Fourth Quarter and Fiscal Year 2025 Financial Results |
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2025 fourth quarter and fiscal year ended March 31, 2025. “We closed out fiscal 2025 on a high note, with record engagement, strong profits, and 20% annual revenue growth,” said Jeff Tangney, co-founder and CEO of Doximity. “Our newsfeed, workflow, and AI tools all hit fresh highs in Q4, helping doctors save time and provide the best car. |
businesswire.com |
2025-05-15 20:01:00 |
Czytaj oryginał (ang.) |
| Kuehn Law Encourages Investors of Doximity, Inc. to Contact Law Firm |
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Doximity, Inc. (NYSE: DOCS) breached their fiduciary duties to shareholders. |
globenewswire.com |
2025-05-15 14:14:00 |
Czytaj oryginał (ang.) |
| Doximity Q4 Earnings Likely to Reflect Strong Product Momentum |
Doximity's Q4 performance likely witnessed strong product-driven gains from new modules and integrated programs, though early revenue pull-forward might have tempered sequential growth. |
zacks.com |
2025-05-12 11:36:03 |
Czytaj oryginał (ang.) |
| Doximity: Strong Fundamentals And Pharma Tailwinds Meet An Overpriced Valuation |
Doximity is experiencing strong user engagement growth, driven by demand from medical prescribers and pharmaceutical marketers. Pharma marketing, Doximity's largest opportunity, is fueling sustained momentum alongside the early success of new platform tools. Integrated features like the client portal drive network effects and boost customer stickiness through real-time marketing insights. |
seekingalpha.com |
2025-05-01 13:23:50 |
Czytaj oryginał (ang.) |
| SOLV vs. DOCS: Which Stock Is the Better Value Option? |
Investors looking for stocks in the Medical Services sector might want to consider either Solventum (SOLV) or Doximity (DOCS). But which of these two companies is the best option for those looking for undervalued stocks? |
zacks.com |
2025-04-29 16:45:45 |
Czytaj oryginał (ang.) |
| Doximity (DOCS) Ascends But Remains Behind Market: Some Facts to Note |
In the closing of the recent trading day, Doximity (DOCS) stood at $56.65, denoting a +0.64% change from the preceding trading day. |
zacks.com |
2025-04-25 23:21:17 |
Czytaj oryginał (ang.) |
| Doximity to Release Fiscal 2025 Fourth Quarter and Full Year Results on May 15, 2025 |
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal fourth quarter and full year ended March 31, 2025 after market close on May 15, 2025. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. To listen to a live audio webcast, please visit the Company's Investor Relations page at https://investors.doximit. |
businesswire.com |
2025-04-24 20:01:00 |
Czytaj oryginał (ang.) |
| Tempus AI vs. Doximity: Which AI in Healthcare Stock is a Better Buy? |
Both TEM and DOCS are technology-intensive healthcare companies leveraging artificial intelligence to enhance their platforms. Which one is a better investment? |
zacks.com |
2025-04-11 20:00:38 |
Czytaj oryginał (ang.) |
| 5 Momentum Stocks to Buy for April Despite a Disappointing March |
Five stocks have strong momentum for April. These are: APP, MRVL, DOCS, RDDT, VEEV. |
zacks.com |
2025-04-01 13:20:43 |
Czytaj oryginał (ang.) |
| Doximity (DOCS) Falls More Steeply Than Broader Market: What Investors Need to Know |
Doximity (DOCS) closed at $60.55 in the latest trading session, marking a -1.51% move from the prior day. |
zacks.com |
2025-03-27 21:20:19 |
Czytaj oryginał (ang.) |
| 3 Medical Services Industry Stocks to Buy as AI Fuels Growth |
The Zacks Medical - Services industry is undergoing a transformation on massive artificial intelligence adoption. COR, DOCS and MD are set to gain the most. |
zacks.com |
2025-03-27 16:15:27 |
Czytaj oryginał (ang.) |
| Doximity (DOCS) Beats Stock Market Upswing: What Investors Need to Know |
The latest trading day saw Doximity (DOCS) settling at $62.99, representing a +0.35% change from its previous close. |
zacks.com |
2025-03-21 21:20:36 |
Czytaj oryginał (ang.) |
| Spotify, Rubrik Lead Five Growth Stocks Regaining This Key Level |
Amid the market correction, few growth stocks are above their 50-day moving averages. Spotify, Rubrik lead five that have reclaimed that level. |
investors.com |
2025-03-17 09:31:26 |
Czytaj oryginał (ang.) |
| Buy These 5 Top-Ranked Stocks to Play Likely Earnings Beat |
Top-ranked stocks Doximity (DOCS), Life Time Group Holdings (LTH), Adtalem Global Education (ATGE), BioMarin Pharmaceutical (BMRN) and Iridium Communications (IRDM) are likely to beat on the bottom line in their upcoming releases. |
zacks.com |
2025-03-12 11:25:23 |
Czytaj oryginał (ang.) |
| 5 Top-Ranked Stocks Poised for an Earnings Beat |
Top-ranked stocks Tenet Healthcare (THC), Fortinet (FTNT), Lyft (LYFT), Garmin (GRMN) and Doximity (DOCS) are likely to beat on the bottom line in their upcoming releases. |
zacks.com |
2025-02-25 10:50:46 |
Czytaj oryginał (ang.) |
| Market Shift: These 3 Stocks Are Winning While Big Tech Lags |
As earnings season winds down, a notable trend has emerged in the markets: several mega-cap stocks have underperformed year-to-date (YTD). In contrast, several mid-to-large cap stocks with strong retail followings have delivered superior returns. |
marketbeat.com |
2025-02-22 10:01:30 |
Czytaj oryginał (ang.) |
| DOXIMITY INVESTOR REMINDER: Scott+Scott Attorneys at Law LLP Investigates Doximity, Inc.'s Directors and Officers for Breach of Fiduciary Duties – DOCS |
NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether the leadership of Doximity, Inc. (“Doximity”) (NYSE: DOCS) breached their fiduciary duties to Doximity and its shareholders. CLICK HERE TO LEARN MORE Scott+Scott is investigating whether members of Doximity's board of directors or senior management failed to manage Doximity in an acceptable manner, in breach of their fiduciary dut. |
businesswire.com |
2025-02-21 11:00:00 |
Czytaj oryginał (ang.) |
| Doximity: Rating Downgrade As Near-Term Upside Is Priced In |
I downgraded Doximity from buy to hold due to expected growth slowdown and current high valuation at 40.5x forward EBITDA. DOCS reported strong Q3 performance with $168.6 million revenue, 25% y/y growth, and 93.3% gross margin, driven by high pharma client demand. New ad products grew over 100% y/y, now contributing >20% of pharma revenue, showing strong underlying demand and expanding advertiser engagement. |
seekingalpha.com |
2025-02-14 19:53:52 |
Czytaj oryginał (ang.) |
| Doximity Momentum, Big Money Support Stays Strong |
Shares of Doximity, Inc. (DOCS) jump on business growth, investor inflows. |
fxempire.com |
2025-02-14 09:49:19 |
Czytaj oryginał (ang.) |
| Doximity (DOCS) is an Incredible Growth Stock: 3 Reasons Why |
Doximity (DOCS) is well positioned to outperform the market, as it exhibits above-average growth in financials. |
zacks.com |
2025-02-12 15:46:13 |
Czytaj oryginał (ang.) |
| Why Doximity (DOCS) Might be Well Poised for a Surge |
Doximity (DOCS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions. |
zacks.com |
2025-02-12 15:20:33 |
Czytaj oryginał (ang.) |
| Doximity (DOCS) is a Great Momentum Stock: Should You Buy? |
Does Doximity (DOCS) have what it takes to be a top stock pick for momentum investors? Let's find out. |
zacks.com |
2025-02-12 15:01:10 |
Czytaj oryginał (ang.) |
| Doximity Q3 Earnings: Outpacing Even Management's Expectations |
I previously rated Doximity, Inc. a buy due to strong Q2 earnings, favorable DCF analysis, and its strategic position in the healthcare industry. Q3 earnings showed continued strength, with DOCS stock up 56% compared to the S&P 500's 2% return since my last analysis. Updated DCF valuation, incorporating management guidance and industry trends, suggests a new price target of $90, indicating 14% upside from today. |
seekingalpha.com |
2025-02-10 14:04:15 |
Czytaj oryginał (ang.) |
| Digital Health Platform Doximity Stock Jumps On Upbeat Annual Outlook, Analysts Raise Forecast |
Doximity Inc DOCS stock is trading higher on Friday after the company reported third-quarter fiscal 2025 results that beat analysts' expectations and upbeat guidance. |
benzinga.com |
2025-02-07 15:24:54 |
Czytaj oryginał (ang.) |
| Why Doximity Stock Skyrocketed Higher Today |
According to data provided by S&P Global Market Intelligence, the "Bloomberg platform for medical professionals," Doximity (DOCS 33.69%), saw its shares spike 34% as of 11:20 a.m. ET Friday. |
fool.com |
2025-02-07 14:01:15 |
Czytaj oryginał (ang.) |
| Doximity shares pop 30% on revenue beat, rosy guidance |
Doximity shares ripped higher Friday, a day after reporting fiscal third-quarter results that beat expectations for revenue and guidance. Analysts called it a "statement type of quarter" for the company. |
cnbc.com |
2025-02-07 12:38:05 |
Czytaj oryginał (ang.) |
| Doximity, Inc. (DOCS) Q3 2025 Earnings Call Transcript |
Doximity, Inc. (DOCS) Q3 2025 Earnings Call Transcript |
seekingalpha.com |
2025-02-06 22:01:09 |
Czytaj oryginał (ang.) |
| Doximity (DOCS) Q3 Earnings and Revenues Top Estimates |
Doximity (DOCS) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.33 per share. This compares to earnings of $0.29 per share a year ago. |
zacks.com |
2025-02-06 20:15:31 |
Czytaj oryginał (ang.) |
| Doximity shares soar 21% after company beats on revenue, raises fiscal year guidance |
Doximity reported third-quarter fiscal 2025 results that beat analysts' expectations for revenue and guidance. The company's revenue increased 25% to $168.6 million in its third quarter. |
cnbc.com |
2025-02-06 19:14:20 |
Czytaj oryginał (ang.) |
| Doximity Surpasses EPS, Revenue Goals |
Doximity (DOCS 0.21%), a digital platform for U.S. medical professionals, released its fiscal third-quarter earnings on Feb. 6, 2025. The company reported impressive results, surpassing both analyst forecasts and its own guidance. |
fool.com |
2025-02-06 18:39:27 |
Czytaj oryginał (ang.) |
| Doximity Ranked #1 Best in KLAS Telehealth Video Platform for Fourth Consecutive Year |
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, announced today that Doximity Dialer has been named 2025 Best in KLAS in the Video Conferencing Platforms segment. This is the fourth consecutive year that Doximity has earned the top position. In addition to securing the #1 spot, Doximity received A-level ratings in all categories, including operations, product, relationship, value, culture, and loyalty. These ratings, whic. |
businesswire.com |
2025-02-06 18:02:00 |
Czytaj oryginał (ang.) |
| Doximity Announces Fiscal 2025 Third Quarter Financial Results |
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2025 third quarter ended December 31, 2024. “We're proud to deliver another quarter of record engagement in Q3, with over 610,000 unique providers using our clinical workflow tools,” said Jeff Tangney, co-founder and CEO of Doximity. “Our AI tools grew the fastest last quarter, up 60% over the prior quarter, while our newsfeed surpassed. |
businesswire.com |
2025-02-06 18:01:00 |
Czytaj oryginał (ang.) |
| Dr Martens recovery plan to be tested in forthcoming update |
Dr Martens PLC (LSE:DOCS) shares have been rising recently, a rare event since the iconic boot maker listed in 2021. New chief executive Ije Nwokorie, ex-Wolff Olins and Apple, came with a lot of goodwill and that has helped but next week's update will be a more serious test. |
proactiveinvestors.co.uk |
2025-01-24 09:20:21 |
Czytaj oryginał (ang.) |
| The Zacks Analyst Blog Doximity, Omnicell, Embecta, Cencora and EDOC |
Doximity, Omnicell, Embecta, Cencora and EDOC are included in this Analyst Blog. |
zacks.com |
2025-01-23 06:45:27 |
Czytaj oryginał (ang.) |
| 3 Medical Services Stocks to Buy to Counter Labor Shortage Woes |
The Zacks Medical - Services industry is growing on nursing care market growth and digital healthcare adoption. DOCS, BTSG and EMBC are set to gain the most. |
zacks.com |
2025-01-03 06:31:11 |
Czytaj oryginał (ang.) |
| 4 Healthcare Stocks Rising More Than 50% in 2024 With Room to Grow |
Medical stocks are expected to reap the benefits of affordable health insurance plans, rising surgeries and widespread adoption of telehealth services in the days ahead. However, inflation and supply-chain woes may act as spoilsport. |
zacks.com |
2024-12-24 12:11:11 |
Czytaj oryginał (ang.) |
| Doximity (DOCS) Ascends But Remains Behind Market: Some Facts to Note |
Doximity (DOCS) closed the most recent trading day at $58.18, moving +0.61% from the previous trading session. |
zacks.com |
2024-12-23 21:21:32 |
Czytaj oryginał (ang.) |
| 4 MedTech Stocks That Gained More Than 100% in 2024 With Room to Run |
Here are some strong MedTech stocks - DOCS, CLOV, CLPT and HIMS - that are expected to provide promising gains. |
zacks.com |
2024-12-23 13:56:10 |
Czytaj oryginał (ang.) |
| This Health Care Software Firm Nears Buy Point After Whopping 101% Year-To-Date Gain |
Doximity stock jumped over 34% following its most recent earnings report on Nov. 11. Now, shares are nearing a buy point. |
investors.com |
2024-12-20 17:20:54 |
Czytaj oryginał (ang.) |
| DOXIMITY ALERT: Bragar Eagel & Squire, P.C. is Investigating Doximity, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm |
NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Doximity, Inc. (NYSE: DOCS) on behalf of long-term stockholders following a class action complaint that was filed against Doximity on April 17, 2024 with a Class Period from February 9, 2022, to April 1, 2024. Our investigation concerns whether the board of directors of Doximity have breached their fiduciary duties to the company. |
globenewswire.com |
2024-12-19 23:00:00 |
Czytaj oryginał (ang.) |
| Doximity initiated with an Equal Weight at Stephens |
Stephens initiated coverage of Doximity with an Equal Weight rating and $55 price target. Doximity runs the "leading digital platform for doctors" and is executing on multiple avenues of growth, though it has "settled into a low-to-mid-teens growth profile," the analyst tells investors. The firm believes the current valuation presumes revenue growth will re-accelerate based on the self-serve marketplace increasing up-sell/cross-sell and new product successes and while it sees potential for EBITDA outperformance, the firm lacks "the visibility and conviction to model above-consensus growth and further margin expansion" as a base case, the analyst tells investors. |
https://thefly.com |
2024-12-19 18:23:28 |
Czytaj oryginał (ang.) |
| Doximity Report Confirms That Telemedicine Serves Key Role in Modern Health Care |
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today released its State of Telemedicine Report, showing that 83% of physician telemedicine users surveyed would like virtual care to remain a permanent part of their clinical practice. Among physicians surveyed, 84% highlighted telemedicine's value in improving continuity of care for patients with chronic or complex conditions, and 96% emphasized its role as a complement to. |
businesswire.com |
2024-12-17 10:00:00 |
Czytaj oryginał (ang.) |
| Prescription for Profits: 3 Must-Buy Healthcare Stocks Before 2025 |
The healthcare sector is undergoing significant changes, with technology, innovation and a patient-centric approach as the cornerstones of its growth. |
zacks.com |
2024-12-16 18:01:09 |
Czytaj oryginał (ang.) |
| Doximity: Strong Fundamentals And Growth Potential Makes It Attractive |
Doximity's dominance in digital healthcare is evident with over 80% of U.S. doctors using the platform, driving strong network effects and competitive positioning. The company boasts impressive financials, with earnings surpassing expectations, strong cash reserves, and high margins, indicating robust scalability and efficiency. New AI-powered features and product launches enhance clinical workflows, while leadership's proven track record supports continued market expansion and service broadening. |
seekingalpha.com |
2024-12-06 09:52:48 |
Czytaj oryginał (ang.) |
| Buy 5 High-Flying Health & Fitness Stocks of 2024 With More Upside |
Five Health & Fitness stocks have strong growth potential for 2025. These are GRMN, SFM, DOCS, PLNT and PTON. |
zacks.com |
2024-12-05 11:35:29 |
Czytaj oryginał (ang.) |
| Doximity initiated with a Neutral at Mizuho |
Mizuho initiated coverage of Doximity with a Neutral rating and $55 price target. The company has witnessed some volatility in quarterly top-line growth over the past few years due to timing of pharma digital ad spending within the Doximity physician user app, including decelerating top-line growth throughout much of FY24, the analyst tells investors in a research note. Mizuho adds that it remains confident in Doximity's ability to generate low double-digit annual revenue growth over the next few years, but also believes that there may be better entry points into the stock. |
https://thefly.com |
2024-12-03 18:31:01 |
Czytaj oryginał (ang.) |
| Are Medical Stocks Lagging Doximity (DOCS) This Year? |
Here is how Doximity (DOCS) and AxoGen (AXGN) have performed compared to their sector so far this year. |
zacks.com |
2024-12-02 17:27:06 |
Czytaj oryginał (ang.) |
| Dr Martens redemption arc will be ‘multi-year event' |
The post-IPO narrative surrounding footwear icon Dr Martens PLC (LSE:DOCS) has been so overwhelmingly negative that it's easy to glance over the green shoots of optimism emerging from the business. While plummeting revenues in the first half filtered through to a pre-tax loss, analysts from broker Peel Hunt noted that the numbers were broadly in line with forecasts. |
proactiveinvestors.co.uk |
2024-11-28 09:36:57 |
Czytaj oryginał (ang.) |
| Dr Martens shares booted higher despite swinging to a loss |
Dr Martens PLC (LSE:DOCS)'s double-digit revenue decline and pre-tax loss in the first half wasn't as bad as it seems, if the market's reaction is anything to go by. Shares in the shoe brand, which has struggled to grow its US sales volumes, added more than 12% following publication of the results. |
proactiveinvestors.co.uk |
2024-11-28 06:34:54 |
Czytaj oryginał (ang.) |
| Dr Martens delivers double-digit sales decline and jumbo pre-tax loss |
Dr Martens PLC (LSE:DOCS) had another unflattering trading performance in the first half of its financial year, with revenues declining 18% year-on-year to £325 million, in line with expectations. The iconic footwear group saw £29 million in losses before tax compared to last year's £26 million profit. |
proactiveinvestors.co.uk |
2024-11-28 05:12:55 |
Czytaj oryginał (ang.) |
| Dr Martens set to unveil loss as all eyes on outlook in results |
Dr Martens PLC (LSE:DOCS)'s first half results on Thursday, 28 November will likely be more about its outlook as a decline in sales and swing to loss are expected. According to Deutsche Bank analysts, revenue is set to have fallen by 18% over the first half, pushing the shoemaker to a “well-flagged” pre-tax loss of £34 million. |
proactiveinvestors.co.uk |
2024-11-27 12:45:32 |
Czytaj oryginał (ang.) |
| 3 Momentum Anomaly Stocks to Buy as Election Rally Fizzles |
DOCS, PI and INOD are currently witnessing a short-term pullback in price. So, make sure you take full advantage of it. |
zacks.com |
2024-11-19 11:56:09 |
Czytaj oryginał (ang.) |
| Looking for Earnings Beat? Buy These 4 Top-Ranked Stocks |
Top-ranked stocks Amazon.com (AMZN), Maplebear Inc. (CART), Exelixis (EXEL) and Doximity (DOCS) are likely to beat on the bottom line in their upcoming releases. |
zacks.com |
2024-11-19 10:20:29 |
Czytaj oryginał (ang.) |
| Surging Earnings Estimates Signal Upside for Doximity (DOCS) Stock |
Doximity (DOCS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions. |
zacks.com |
2024-11-15 15:20:19 |
Czytaj oryginał (ang.) |